pharma · Multiple Myeloma · Ovarian Cancer · CASIF
CASI Pharmaceuticals
CASI Pharmaceuticals clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 601 Gateway Blvd, San Francisco, CA 94080, US
- Employees
- 44
- Programs
- 22
- Drugs
- 11
- Patents
- 2
CASI Pharmaceuticals projects
5 ClinicalTrials.gov programs sponsored by CASI Pharmaceuticals.
CASI Pharmaceuticals has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CID-103
CASI Pharmaceuticals
Multiple Myeloma
1 trial -
ENMD-2076
CASI Pharmaceuticals
Advanced Cancer
1 trial -
ENMD-2076
CASI Pharmaceuticals
Multiple Myeloma
1 trial -
ENMD-2076
CASI Pharmaceuticals
Relapsed or Refractory Hematological Malignancies
1 trial -
MKC-1
CASI Pharmaceuticals
Hematological Malignancies
1 trial
Frequently asked questions
How many clinical projects does CASI Pharmaceuticals have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.